Warning letter
Homeocare Laboratories, Inc.: warning letter of Jun 22, 2020
FDA warning letter 603532 · Division of Pharmaceutical Quality Operations I
Key facts
| Reference number | 603532 |
|---|---|
| Company | Homeocare Laboratories, Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jun 22, 2020 |
| Posted date | Jun 30, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations I |
| Product type | Drugs |
| CFR sections cited | 211.34, 310.530, 211.67(a), 211.84(d)(1), 211.100(a), 211.165(a) |
| Inspection city | Yonkers |
| Inspection ZIP | 10701-1407 |
| Inspection start date | Dec 2, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: